Triglav Skladi D.O.O. Invests $1.34 Million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Triglav Skladi D.O.O. purchased a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,000 shares of the biotechnology company’s stock, valued at approximately $1,337,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of SRPT. Park Avenue Securities LLC purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter worth about $205,000. Smith Salley Wealth Management purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter worth about $889,000. UMB Bank n.a. lifted its holdings in shares of Sarepta Therapeutics by 36.0% in the fourth quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company’s stock worth $63,000 after buying an additional 138 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its stake in Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 156 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its stake in Sarepta Therapeutics by 23.1% in the fourth quarter. Nisa Investment Advisors LLC now owns 1,317 shares of the biotechnology company’s stock valued at $160,000 after purchasing an additional 247 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Sarepta Therapeutics

In related news, Director Claude Nicaise sold 2,491 shares of the firm’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares of the company’s stock, valued at $2,771,187.68. This trade represents a 8.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 7.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on SRPT shares. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a research note on Wednesday, March 19th. Needham & Company LLC lowered their target price on shares of Sarepta Therapeutics from $183.00 to $125.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Piper Sandler lowered their target price on shares of Sarepta Therapeutics from $110.00 to $70.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 7th. Evercore ISI downgraded shares of Sarepta Therapeutics from an “outperform” rating to an “inline” rating and set a $50.00 target price on the stock. in a research note on Thursday, May 8th. Finally, Wells Fargo & Company lowered their target price on shares of Sarepta Therapeutics from $115.00 to $100.00 and set an “overweight” rating on the stock in a research note on Thursday, May 8th. Six research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $124.36.

Sarepta Therapeutics Stock Up 3.3%

Shares of Sarepta Therapeutics stock opened at $36.43 on Monday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics, Inc. has a 52-week low of $34.10 and a 52-week high of $173.25. The stock has a market capitalization of $3.58 billion, a price-to-earnings ratio of 29.14 and a beta of 0.85. The company’s 50 day moving average price is $60.11 and its 200-day moving average price is $97.18.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The firm had revenue of $744.86 million during the quarter, compared to the consensus estimate of $685.75 million. During the same quarter in the prior year, the business posted $0.73 EPS. The firm’s revenue for the quarter was up 80.2% on a year-over-year basis. Equities research analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.